{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:08:12Z","timestamp":1784650092084,"version":"3.55.0"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematol. Rep.","Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: Thrombotic microangiopathies are rare, life-threatening hematological disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end-organ injury. This study was conducted in a setting where ADAMTS13 activity testing became available only from 2015 onward and complement-targeted therapy (eculizumab) had limited accessibility throughout most of the study period, conditions that shaped both diagnostic classification and treatment outcomes. Their clinical presentation, treatment response, and prognosis vary according to etiology, making early recognition and subtype classification clinically important. This study aimed to evaluate the etiological distribution, clinical features, treatment responses, and outcomes of adult patients with thrombotic microangiopathy at a tertiary-center real-world cohort. Methods: This retrospective cohort study included 47 adult patients (\u226518 years) hospitalized with thrombocytopenia and microangiopathic hemolytic anemia (MAHA) in a nine-year period. Patients were classified as thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or secondary TMA based on clinical and laboratory evaluation. Demographic characteristics, clinical manifestations, laboratory parameters, treatments, and outcomes were analyzed. Results: The mean age was 45.3 \u00b1 15.2 years, and 72.3% of patients were female. Primary thrombotic microangiopathy accounted for 74.5% of cases, including thrombotic thrombocytopenic purpura in 53.2% and hemolytic uremic syndrome in 21.2%; secondary thrombotic microangiopathy accounted for 25.5%. Hemodialysis was required in all patients with hemolytic uremic syndrome compared with 16% of those with thrombotic thrombocytopenic purpura. The complete response rate was 74.5%, and in-hospital mortality was 25.5%. In multivariable Cox regression analysis, treatment non-response and reduced post-treatment estimated glomerular filtration rate independently predicted mortality. Conclusions: Adult TMAs are characterized by considerable etiological and clinical heterogeneity, which makes differential diagnosis challenging, particularly in settings where access to contemporary diagnostic tests and targeted treatments is limited. In this cohort, in the absence of ADAMTS13 testing, TTP was the most frequent subtype, while treatment non-response and renal impairment emerged as the main factors associated with mortality. These findings emphasize the need for early clinical recognition and careful subtype-based differential diagnosis, which will reduce morbidity and mortality by permitting rapid initiation of pathophysiology-based appropriate interventions, i.e., PEx, immune suppression and caplacizumab for immune TTP and anti-complement therapy for aHUS, and limiting the inappropriate use of PEx with its complications, including sepsis.<\/jats:p>","DOI":"10.3390\/hematolrep18040049","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:17:52Z","timestamp":1784647072000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Spectrum and Differential Diagnosis of Adult Thrombotic Microangiopathies: Real-World Experience from a Tertiary Referral Center"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2693-0486","authenticated-orcid":false,"given":"Nazl\u0131 Pelin","family":"K\u0131rkayak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ankara Bilkent City Hospital, Ankara 06800, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-5978","authenticated-orcid":false,"given":"Gulsum","family":"Ozet","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Bilkent City Hospital, Ankara 06800, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-2043","authenticated-orcid":false,"given":"Simten","family":"Dagdas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Bilkent City Hospital, Ankara 06800, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-7614","authenticated-orcid":false,"given":"Funda","family":"Ceran","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Bilkent City Hospital, Ankara 06800, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-6229","authenticated-orcid":false,"given":"Ihsan","family":"Ates","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ankara Bilkent City Hospital, Ankara 06800, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mullapudi, J., and Bhat, R. (2025). Clinical profile and outcomes of thrombotic microangiopathy\u2014A prospective study from a tertiary centre in India. Res. Sq.","DOI":"10.21203\/rs.3.rs-7744574\/v1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2018-02-791533","article-title":"The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis","volume":"132","author":"Masias","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.20166","article-title":"Rituximab for treatment of refractory\/relapsing thrombotic thrombocytopenic purpura (TTP)","volume":"77","author":"Ahmad","year":"2004","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood.V96.4.1223","article-title":"How I treat patients with thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome","volume":"96","author":"George","year":"2000","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nguyen, M., Dileep, G., Patel, S., Al Ammary, F., Tran, M.-H., Lee, B.J., Ciurea, S., Desai, S., Amin, A., and Zhao, H. (2025). Thrombotic microangiopathy multidisciplinary assessment team: Demographics, final diagnosis, treatment, and outcomes. BMC Nephrol., 26.","DOI":"10.1186\/s12882-025-04446-z"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: A review","volume":"81","author":"Genest","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MOH.0000000000000687","article-title":"Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy","volume":"28","author":"Schoettler","year":"2021","journal-title":"Curr. Opin. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mrabet, S., Dardour, G., Boukadida, R., Emah, S., Sahtout, W., and Zellama, D. (2025). Spectrum and outcomes of thrombotic microangiopathies in nephrology: A 17-year cohort from a North African center. BMC Nephrol., 26.","DOI":"10.1186\/s12882-025-04542-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e12708","DOI":"10.1002\/rth2.12708","article-title":"Thrombotic microangiopathies: An illustrated review","volume":"6","author":"Kapoor","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/art.42681","article-title":"Clinical evaluation and management of thrombotic microangiopathy","volume":"76","author":"Leisring","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Coppo, P., Schwarzinger, M., Buffet, M., Wynckel, A., Clabault, K., Presne, C., Poullin, P., Malot, S., Vanhille, P., and Azoulay, E. (2010). Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA reference center experience. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010208"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study","volume":"43","author":"Guardia","year":"2010","journal-title":"Transfus. Apher. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1111\/j.1537-2995.2012.03635.x","article-title":"Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura","volume":"52","author":"Bhagirath","year":"2012","journal-title":"Transfusion"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11239-020-02094-8","article-title":"When to consider targeted therapies in thrombotic microangiopathies in the modern era: Walking the tightrope between cost, safety, and efficacy","volume":"49","author":"Murphree","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Blasco, M., Guill\u00e9n-Olmos, E., Diaz-Ricart, M., and Palomo, M. (2022). Complement mediated endothelial damage in thrombotic microangiopathies. Front. Med., 9.","DOI":"10.3389\/fmed.2022.811504"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s00134-012-2638-5","article-title":"Causes and risk factors of death in patients with thrombotic microangiopathies","volume":"38","author":"Peigne","year":"2012","journal-title":"Intensive Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5045\/br.2018.53.2.130","article-title":"Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia","volume":"53","author":"Yap","year":"2018","journal-title":"Blood Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ijgo.14918","article-title":"Long-term survival and renal outcomes of thrombotic microangiopathy in pregnancy: A retrospective cohort study","volume":"163","author":"Chen","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hwang, S., Kim, G.W., Cho, S.H., and Lim, K.H. (2024). Clinical characteristics and treatment courses of trauma-induced thrombotic microangiopathy: A retrospective study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216527"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:48:53Z","timestamp":1784648933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["hematolrep18040049"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18040049","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}